Missing Script

Get updates

Evidence Explorer / MS-N206 / Supportive physical care / Appraised November 1, 2026

Neuromuscular electrical stimulation (NMES) was tested as a home exercise substitute during palliative chemotherapy for non-small-cell lung cancer. The study’s feasibility target was not met, and no clear strength, muscle-mass or activity benefit emerged.

Evidence at a glance

  • Population: 49 randomized; 30 assigned to NMES, with 18 eligible for the primary adherence analysis.
  • Regimen: quadriceps stimulation for 30 minutes, ideally daily and at least three times weekly during chemotherapy.
  • Feasibility result: 9 of 18 met the minimum target—50% (90% CI 29%–71%) vs an 80% acceptability threshold.
  • Clinical result: no clear difference in strength, thigh lean mass or physical activity.
  • Evidence label: negative feasibility evidence.

What was studied

This randomized phase II study asked a pragmatic question: can people receiving palliative chemotherapy use NMES often enough for it to be useful? Attrition left only 18 participants in the primary adherence analysis, and half met the minimum schedule.

No serious NMES-related adverse events were reported. However, a device can be safe in a small trial and still fail because burden, fatigue, illness progression or treatment schedules make adherence unrealistic.

What this evidence cannot establish

The study was not powered as a definitive efficacy trial and had substantial attrition. Its negative feasibility result should not be generalized to all cancers, earlier stages, supervised rehabilitation or different NMES devices.

No improvement in muscle measures means the intervention should not be described as preserving muscle in this setting.

Practical safety context

Electrical stimulation should be cleared with the cancer-rehabilitation or oncology team, especially with implanted electrical devices, significant arrhythmia concerns, thrombosis, skin lesions, severe neuropathy or tumor involvement near the electrode area.

Electrode burns, pain and muscle soreness are possible if intensity or placement is inappropriate.

Questions for the care team

  • Is supervised exercise feasible and better matched to my goals?
  • Do I have device, clotting, skin or neurologic contraindications?
  • What adherence threshold and functional outcome would justify continuing?

Sources

Source note: Full text, PubMed metadata and registry information were checked. Funding and conflict information is reported only where it was available in the checked source. No correction, retraction or expression of concern was identified in the PubMed-linked record on November 1, 2026.

This record is educational. It is not a personal treatment recommendation and does not replace advice from the oncology or radiation-care team. Symptom or toxicity outcomes do not demonstrate tumor response, recurrence prevention or longer survival.